Gilead's Experimental HIV Treatment Shows Low Discontinuation Rates in Studies

Published Date: 27 Feb 2026

Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was ⁠generally well tolerated with low discontinuation rates, positioning the single-tablet...

Read Full News

Latest News

Is AD Transmissible? The Evidence for ‘Iatrogenic’ Disease

Evidence for medically transmitted amyloid pathology is mounting, but whether Alzheimer’s disease itself can be transmitted — and what it means for patients — remains unsettled.

Dr Reddy's Signs India Distribution Deal for Takeda's Qdenga Dengue Vaccine

Dr Reddy's Laboratories said on Friday it had ⁠signed an agreement with Japanese drugmaker Takeda Pharmaceutical to ⁠promote and distribute the Qdenga dengue vaccine in...

Screwworm Infests US Horse Before Port Reopens to Mexican Livestock

The U.S. confirmed a case of New World screwworm in a horse in New Mexico on Thursday, as the ⁠federal government prepared to resume imports of Mexican livestock into the...

CDC Delay Holds Up Children's COVID Vaccine Orders, WSJ Reports

U.S. states are facing delays in obtaining COVID-19 vaccines for children through a federal immunization program, the Wall Street Journal reported ⁠Wednesday, citing people...

Exclusive-Pennsylvania Asks for CDC Measles Help Amid Kennedy Dispute

The Pennsylvania health department has requested emergency support from the US CDC as it grapples with one of the country's largest and most deadly measles outbreaks, though...

Older Adults Living With HIV: A New Focus on Healthy Aging

The growing number of older adults with HIV brings multimorbidity, functional decline, stigma, and end-of-life planning to long-term care.

Todays Updates

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis Marco Meglio

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

This Week on NeurologyLive® — October 5, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses Louie Pasculli

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease Marco Meglio

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease Louie Pasculli

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Todays Updates

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis Marco Meglio

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

This Week on NeurologyLive® — October 5, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses Louie Pasculli

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease Marco Meglio

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease Louie Pasculli

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Latest News

Evidence for medically transmitted amyloid pathology is mounting, but whether Alzheimer’s disease itself can be transmitted — and what it means for patients — remains unsettled.

Dr Reddy's Laboratories said on Friday it had ⁠signed an agreement with Japanese drugmaker Takeda Pharmaceutical to ⁠promote and distribute the Qdenga dengue vaccine in...

The U.S. confirmed a case of New World screwworm in a horse in New Mexico on Thursday, as the ⁠federal government prepared to resume imports of Mexican livestock into the...

U.S. states are facing delays in obtaining COVID-19 vaccines for children through a federal immunization program, the Wall Street Journal reported ⁠Wednesday, citing people...

The Pennsylvania health department has requested emergency support from the US CDC as it grapples with one of the country's largest and most deadly measles outbreaks, though...

The growing number of older adults with HIV brings multimorbidity, functional decline, stigma, and end-of-life planning to long-term care.

News All Time

Daily Probiotic Fails to Prevent Infections in Infants

Daily use of an oral probiotic from 6 to 24 months of age may not reduce the occurrence of ear or respiratory tract infections and antibiotic use in healthy infants.

Once-Monthly PrEP Drug Could Be Manufactured for $3 a Year

The current agreement manufacturer Merck has signed for global access to its once-monthly alimatravir would exclude countries with more than 230,000 new HIV acquisitions a year.

Testing for Duffy-Null Neutrophil Count Before Consult

By adding Duffy antigen testing to routine blood bank screens, VA identified 79 DANC patients, sparing many unnecessary bone marrow biopsies.

WHO Says Staff Shortage, Funding Challenges Hamper Congo Ebola Response

Shortages of trained staff, operational partners and funding are causing a bottleneck in efforts to expand the Ebola response in the Democratic Republic of Congo as the...

Lessons From Recent Viral Outbreaks

Despite advances in diagnostics and trial speeds, gaps in clinical care capacity, targeted therapies, and public communication threaten global preparedness for the next pandemic.

Cyclosporiasis Cases in Michigan Climb to Over 14,700, State Health Officials Say

Michigan health officials reported 14,718 cases linked to an outbreak of cyclosporiasis on Thursday, an increase ⁠of 208 cases since its last update a week...

Salmonella Outbreak Linked to Pumpkin Seeds Infects 81 in France

An outbreak of salmonella related to ⁠a batch of pumpkin seeds infected 81 people, ⁠hospitalising six, in several French regions between ⁠May and August, ‌the Health and...

As Schools Re-open, Congo Drops Remote Learning Plan in Ebola Red Zone

Schools reopened this week in areas of Democratic Republic of Congo hardest hit by Ebola, after authorities decided the risk of transmission ⁠was outweighed by the risk of...

WHO's Tedros Says Ebola Response Must Be Scaled Up to Tackle Congo Outbreak

The head of the World Health Organization on Wednesday said the Ebola response needs to be scaled up to tackle the outbreak in the Democratic Republic ⁠of Congo, with...

Gepotidacin as Effective as Standard Therapy for Gonorrhea

Nucleic acid amplification test-confirmed success rates for urogenital gonorrhea are high and similar to those of oral gepotidacin and ceftriaxone plus azithromycin, a phase 3 trial shows.

Health Officials Turn to Mobile-phone Data to Track Ebola Spread in Congo

Health officials battling the Ebola outbreak in eastern Democratic Republic of Congo are using anonymised mobile-phone data to map population movements and identify areas...

GSK to Advance MRNA Flu Vaccine to Late-stage Trial

(Corrects paragraph 4 to clarify that GSK plans to start more than 20, ⁠not 25, late-stage trials in 2026)

UK Pledges Additional £50 Million to Help Contain Ebola Outbreak in Congo

Britain said on Tuesday it would provide more than £50 ⁠million ($67.56 million) in new funding to support efforts to contain an ⁠Ebola outbreak in the Democratic Republic...

Congo's Ebola Outbreak Kills More Than 3,000, Government Figures Show

The number of deaths in Democratic Republic of Congo's Ebola outbreak has surpassed 3,000, government ⁠data showed on Wednesday, as the country's worst-ever epidemic...

USDA Cyclospora Research Projects Shelved Amid Funding Cuts and Relocations, Politico Reports

The Trump administration is shuttering two of the three U.S. Department of Agriculture research projects studying cyclospora, ⁠a foodborne parasite that has sickened...

Measles Cases in Pennsylvania Rise to 460 Amid Ongoing Outbreak

Pennsylvania's health department said on Friday the confirmed number of cases linked to a measles ⁠outbreak has reached 460 this year, an increase of 36 over its update two...

Recommended News For You

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.

Integrative palliative care is critical to improving mental health among pancreatic cancer patients

Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing

How Do Younger People Fare With Stool Tests for CRC Screening?

De-escalation Misses the Mark in Inflammatory Breast Cancer

Waiting for a Sharp Increase in Prostate Cancer Cases.

Recommended Articles For You

Obesity is a major risk factor for cancer 

Ferroptosis-Modulating Therapeutics in Precision Oncology 

Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies 

Red Cell Deformability as a Target in Critical Illness 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals

2.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

3.

Preschoolers With Cancer Have Poor Motor Skills

4.

When it comes to obesity-related cancers, where you shop for food matters

5.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

1.

Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy

2.

From Bench to Bedside: The New Era of Lymphoma Treatment and Education

3.

Red Cell Deformability as a Target in Critical Illness

4.

Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier

5.

Tumor Mutation Signatures From Replication Stress: Mechanisms, Clinical Implications, and Emerging Therapeutic Insights

1.

International Conference on Cancer Nursing and Rehabilitation Strategies

2.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

3.

International Conference on Innovations in Critical Care for Oncology and Cardiology

4.

International Symposium on Oncology, Cardiology and Critical Care Innovations

5.

International Conference on Cancer Nursing and Hematology Support

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

2.

Signs and Symptoms of Leukemia

3.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

4.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

5.

Navigating the Complexities of Ph Negative ALL - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot